HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline SABCS 2021 - 1 week	exemestane Sensitive: A2 - Guideline SABCS 2021 - 1 week
ESR1 mutation + HR positive ESR1 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ESR1 mutation + HR positive ESR1 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials SABCS 2021 - 1 week	palbociclib Sensitive: B - Late Trials SABCS 2021 - 1 week
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval JAMA Oncol - 1 week	palbociclib Sensitive: A1 - Approval JAMA Oncol - 1 week
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval FDA - 1 week	abemaciclib Sensitive: A1 - Approval FDA - 1 week
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib + letrozole Sensitive: B - Late Trials SABCS 2021 - 1 week	ribociclib + letrozole Sensitive: B - Late Trials SABCS 2021 - 1 week
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC Sensitive: C4 – Case Studies Front Endocrinol (Lausanne) - 1 week	EC Sensitive: C4 – Case Studies Front Endocrinol (Lausanne) - 1 week
PIK3CA H1047R + PIK3CA D959N + ER E380Q PIK3CA H1047R + PIK3CA D959N + ER E380Q	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA H1047R + PIK3CA D959N + ER E380Q PIK3CA H1047R + PIK3CA D959N + ER E380Q	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Resistant: C4 – Case Studies Front Endocrinol (Lausanne) - 1 week	abemaciclib Resistant: C4 – Case Studies Front Endocrinol (Lausanne) - 1 week
HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative HR negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AMG479 Sensitive: C3 – Early Trials Nature - 2 weeks	AMG479 Sensitive: C3 – Early Trials Nature - 2 weeks
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	eribulin mesylate Sensitive: C2 – Inclusion Criteria SAGE Journals - 3 weeks	eribulin mesylate Sensitive: C2 – Inclusion Criteria SAGE Journals - 3 weeks
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval	ribociclib Sensitive: A1 - Approval
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval	alpelisib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A1 - Approval	everolimus Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval	olaparib Sensitive: A1 - Approval
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A1 - Approval	fulvestrant Sensitive: A1 - Approval
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CaT Sensitive: A2 - Guideline	CaT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline	eribulin mesylate Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline	letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline	ribociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel Sensitive: A2 - Guideline	docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	bevacizumab Sensitive: A2 - Guideline	bevacizumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: A2 - Guideline	albumin-bound paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ixabepilone Sensitive: A2 - Guideline	ixabepilone Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline	capecitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline	gemcitabine Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline	vinorelbine tartrate Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	toremifene Sensitive: A2 - Guideline	toremifene Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline	letrozole Sensitive: A2 - Guideline
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline	anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + docetaxel Sensitive: A2 - Guideline	carboplatin + docetaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	tamoxifen Sensitive: A2 - Guideline	tamoxifen Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	everolimus Sensitive: A2 - Guideline	everolimus Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TC Sensitive: A2 - Guideline	TC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline	fulvestrant Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + anastrozole Sensitive: A2 - Guideline	fulvestrant + anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant + letrozole Sensitive: A2 - Guideline	fulvestrant + letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline	palbociclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline	abemaciclib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	exemestane Sensitive: A2 - Guideline	exemestane Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor Sensitive: A2 - Guideline	Aromatase inhibitor Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline	carboplatin + paclitaxel Sensitive: A2 - Guideline
ER positive + PGR positive ER positive + PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive + PGR positive ER positive + PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline	anastrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC Sensitive: A2 - Guideline	EC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CMF Sensitive: A2 - Guideline	CMF Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline	paclitaxel Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	AC Sensitive: A2 - Guideline	AC Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TAC Sensitive: A2 - Guideline	TAC Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	fulvestrant Sensitive: A2 - Guideline	fulvestrant Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline	letrozole Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GT Sensitive: A2 - Guideline	GT Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	epirubicin Sensitive: A2 - Guideline	epirubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	cyclophosphamide oral Sensitive: A2 - Guideline	cyclophosphamide oral Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline	lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline	doxorubicin hydrochloride Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	estradiol Sensitive: A2 - Guideline	estradiol Sensitive: A2 - Guideline
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	megestrol Sensitive: A2 - Guideline	megestrol Sensitive: A2 - Guideline
HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR negative + PD-L1 expression HR negative + PD-L1 expression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	atezolizumab Sensitive: A2 - Guideline	atezolizumab Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline	carboplatin Sensitive: A2 - Guideline
PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	anastrozole Sensitive: A2 - Guideline	anastrozole Sensitive: A2 - Guideline
PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PGR positive PGR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	letrozole Sensitive: A2 - Guideline	letrozole Sensitive: A2 - Guideline
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
BRCA2 mutation + HR positive BRCA2 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA2 mutation + HR positive BRCA2 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
BRCA1 mutation + HR positive BRCA1 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation + HR positive BRCA1 mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A2 - Guideline	olaparib Sensitive: A2 - Guideline
HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HER-2 negative HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	POL 6326 Sensitive: B - Late Trials	POL 6326 Sensitive: B - Late Trials
PIK3CA mutation + ER positive PIK3CA mutation + ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + ER positive PIK3CA mutation + ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials	GDC-0032 Sensitive: B - Late Trials
PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials	gimeracil/oteracil/tegafur Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials	palbociclib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PI3K inhibitor Sensitive: B - Late Trials	PI3K inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	DJ 927 Sensitive: B - Late Trials	DJ 927 Sensitive: B - Late Trials
BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA2 mutation BRCA2 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials	ABT-888 Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials	albumin-bound paclitaxel Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SNDX-275 Resistant: B - Late Trials	SNDX-275 Resistant: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	capecitabine + DJ 927 Sensitive: B - Late Trials	capecitabine + DJ 927 Sensitive: B - Late Trials
ER positive + PGR negative + HER-2 negative ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive + PGR negative + HER-2 negative ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials	ribociclib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: B - Late Trials	CDK6 inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Sensitive: B - Late Trials	CDK4 inhibitor Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials	chidamide Sensitive: B - Late Trials
PIK3CA E542K + HR positive PIK3CA E542K + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA E542K + HR positive PIK3CA E542K + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
PIK3CA H1047X PIK3CA H1047X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA H1047X PIK3CA H1047X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
PIK3CA E545X PIK3CA E545X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA E545X PIK3CA E545X	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials	alpelisib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0032 Sensitive: B - Late Trials	GDC-0032 Sensitive: B - Late Trials
TP53 mutation TP53 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	TP53 mutation TP53 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Resistant: B - Late Trials	talazoparib Resistant: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	SHR6390 Sensitive: B - Late Trials	SHR6390 Sensitive: B - Late Trials
ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER mutation ER mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	Aromatase inhibitor + palbociclib Resistant: B - Late Trials	Aromatase inhibitor + palbociclib Resistant: B - Late Trials
HIF1A overexpression HIF1A overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HIF1A overexpression HIF1A overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials	albumin-bound paclitaxel Sensitive: B - Late Trials
BACH1 overexpression BACH1 overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BACH1 overexpression BACH1 overexpression	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	albumin-bound paclitaxel Sensitive: B - Late Trials	albumin-bound paclitaxel Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	oral paclitaxel/encequidar Sensitive: B - Late Trials	oral paclitaxel/encequidar Sensitive: B - Late Trials
BRCA1 mutation+ HER-2 negative BRCA1 mutation+ HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA1 mutation+ HER-2 negative BRCA1 mutation+ HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
BRCA2 mutation + HER-2 negative BRCA2 mutation + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	BRCA2 mutation + HER-2 negative BRCA2 mutation + HER-2 negative	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: B - Late Trials	olaparib Sensitive: B - Late Trials
ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ER positive ER positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	EC-P Sensitive: B - Late Trials	EC-P Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CT7001 Sensitive: B - Late Trials	CT7001 Sensitive: B - Late Trials
HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	HR positive HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	docetaxel Sensitive: B - Late Trials	docetaxel Sensitive: B - Late Trials

HER2 Negative Breast Cancer

Associations(304)

Associations
(304)